Learning Needs in Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is a heterogeneous disorder that involves a shortage of platelets, or thrombocytes, and can result in excessive bruising or bleeding. Diagnosis and treatment are challenging due to the lack of specific diagnostic criteria and the widely varying clinical features: some patients remain asymptomatic, whereas others experience troublesome bruising or even life-threatening intracranial hemorrhage. The optimal management of ITP necessitates an individualized approach that...

COVID-19: Impact on Cancer Research and Care

The COVID-19 pandemic has impacted multiple aspects of oncology, including patient care, research, continuing medical education (CME), and cancer care providers' psychological well-being, according to survey data presented today at the European Society of Medical Oncology (ESMO) Virtual Congress 2020. "The ongoing SARS-CoV-2 pandemic and ensuing coronavirus disease (COVID-19) is challenging cancer care and services worldwide," report the investigators, led by Guy Jerusalem, MD, PhD, Head of Medi...

The Changing Standards for FDA Oncology Approvals: Talal Hilal, MD

The FDA approval process is in place to ensure that drugs are safe and effective before they are made available to the public. But do the clinical trials that lead to approval truly ascertain whether a drug is efficacious? Fully two-thirds of anticancer drug clinical trials leading to FDA approvals between 2014 and 2019 had at least one important limitation in trial design: lack of randomization, lack of significant overall survival advantage, inappropriate use of crossover, and/or use of a...

Oncology Practice and COVID-19: Addressing the Challenges With Mark A. Lewis, MD

The COVID-19 pandemic has created multiple challenges to cancer care, ranging from the risk of exposure to novel coronavirus involved in having patients come to the hospital or clinic for treatment to the risks that immunosuppressive cancer treatments––and cancer itself––may pose in making patients more susceptible to COVID-19. How should these risks be balanced against the necessity of life-preserving cancer therapies? Mark A. Lewis, MD, Director of Gastrointestinal Oncology at Intermountain He...

Cancer Research and the Art of Spin

At oncology meetings, nearly one third of oral presentations on cancer clinical trials where the primary end point was not met presented a positive, or "not negative," conclusion about a formally negative result, according to results of a quality improvement analysis now published in JAMA Oncology. "Presentations at medical meetings have great resonance within the scientific community, especially following the diffusion of social media," write the investigators, led by first author Massimo Di Ma...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts